Journal des complications et de la médecine du diabète

Empagliflozin's Novel Cardioprotective Mechanism in Non-Diabetic Myocardial Infarction with Acute Hyperglycemyocardial Infarction

Abstract

Arundhati Guru

Individuals who experienced both acute myocardial infarction and hyperglycaemic myocardial infarction upon admission to the hospital had a worse prognosis than those who did not. The ability of sodium-glucose co-transporter-2 myocardial infarction inhibitors to treat acute hyperglycaemic myocardial infarction and the underlying processes remains unknown. When non-diabetic myocardial infarction caused by a glucose injection cooccurred with acute hyperglycaemic myocardial infarction in WT myocardial infarction. The survival rate was lower than in the control group. After using empagliflozin, a notable improvement in LV function and survival was seen. Also, when a myocardial infarction was coupled with an acute hyperglycaemic myocardial infarction, empagliflozin decreased fibrosis and autophagy of border cardiac tissue.